SG/PUT/GILEAD SCIENCES/60/0.1/21.03.25 | Real-time Bid/Ask 10:47:01 2024-07-08 EDT | ||
| 0.27 EUR / 0.28 EUR | -11.29% |
|
| Current month | +24.00% | ||
| 1 month | -18.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-08 | 0.24 | -22.58% |
| 24-07-05 | 0.31 | +3.33% |
| 24-07-04 | 0.3 | +20.00% |
| 24-07-03 | 0.25 | +4.17% |
| 24-07-02 | 0.24 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 02:26 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SY0NTE |
| ISIN | DE000SY0NTE4 |
| Date issued | 2024-05-21 |
| Strike | 60 $ |
| Maturity | 2025-03-21 (256 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.45 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.01 € |
| Spread % | 3.70% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.69
USD
Average target price
83.34
USD
Spread / Average Target
+24.96%
- Stock Market
- Warrants
- Warrant
